ObsEva (NASDAQ:OBSV) Cut to “Sell” at StockNews.com

ObsEva (NASDAQ:OBSVGet Rating) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Thursday.

OBSV has been the topic of several other reports. HC Wainwright dropped their target price on shares of ObsEva from $15.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, March 28th. Canaccord Genuity Group started coverage on shares of ObsEva in a research note on Tuesday, April 26th. They set a “buy” rating and a $12.00 price objective on the stock. Zacks Investment Research downgraded shares of ObsEva from a “hold” rating to a “sell” rating in a research note on Thursday, March 31st. Aegis assumed coverage on ObsEva in a research report on Monday, March 28th. They set a “buy” rating and a $12.00 target price on the stock. Finally, Canaccord Genuity Group began coverage on ObsEva in a research report on Tuesday, April 26th. They issued a “buy” rating and a $12.00 price target for the company. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $11.88.

Shares of NASDAQ:OBSV opened at $1.48 on Thursday. The business’s 50 day moving average is $1.39 and its 200 day moving average is $1.74. The stock has a market cap of $115.40 million, a P/E ratio of -1.87 and a beta of 0.67. ObsEva has a 52-week low of $1.08 and a 52-week high of $3.58. The company has a quick ratio of 2.70, a current ratio of 2.70 and a debt-to-equity ratio of 0.80.

ObsEva (NASDAQ:OBSVGet Rating) last issued its earnings results on Thursday, March 10th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.04). On average, sell-side analysts anticipate that ObsEva will post -1.14 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of OBSV. Morgan Stanley lifted its holdings in shares of ObsEva by 2,713.1% during the second quarter. Morgan Stanley now owns 863,112 shares of the company’s stock worth $2,615,000 after purchasing an additional 832,430 shares during the period. BlackRock Inc. acquired a new stake in ObsEva during the 4th quarter valued at approximately $999,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in ObsEva by 15.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 668,485 shares of the company’s stock valued at $1,009,000 after acquiring an additional 90,359 shares during the period. Toroso Investments LLC purchased a new stake in shares of ObsEva in the 3rd quarter valued at $199,000. Finally, Geode Capital Management LLC increased its stake in shares of ObsEva by 229.4% in the third quarter. Geode Capital Management LLC now owns 82,227 shares of the company’s stock worth $255,000 after acquiring an additional 57,261 shares during the period. Hedge funds and other institutional investors own 27.80% of the company’s stock.

About ObsEva (Get Rating)

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Recommended Stories

Analyst Recommendations for ObsEva (NASDAQ:OBSV)

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.